HAEMATO AG: Corporate News

Schönefeld (pta006/28.11.2016/08:00 UTC+1) Corporate News of HAEMATO AG:
31.6 % sales growth and 47.3% profit growth in first 9 month period 2016 compared to the prior-year period

In the first 9 months of 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS sales of EUR 213.10 million (prior-year period: EUR 161.99 million) and profit of EUR 6.61 million (prior-year period: EUR 4.49 million). In the third quarter alone, sales amounted to EUR 70.83 million (prior-year quarter: EUR 60.52 million).
"HAEMATO Group increased significant sales and profit in the first 9 month period 2016. We are glad to see profit growing disproportionate and are confident that this will be the result in the fourth quarter as well", says Dr Christian Pahl, Member of the Management Board of HAEMATO AG.

About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. Botulinum preparations and hyaluronic acid are strong growing product lines.

HAEMATO AG is listed in the Entry Standard (Open Market) on the
Frankfurt Stock Exchange.
Key figures for the share of HAEMATO AG:
Subscribed capital: EUR 20,778,898
Listed shares: ordinary shares
ISIN: DE000619070
WKN: 619070
Stock symbol: HAE
Dividend payments: 2014/2015/2016: 0.30 Euro/share

(end)

Emitter:	HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany
Contact Person:	Dr. Christian Pahl
Phone:	+49 30 8973086-70
E-Mail:	ir@haemato.de
Website:	www.haemato-ag.de
ISIN(s):	DE0006190705 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate